Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: An adjusted indirect comparison meta-analysis of randomized clinical trials

Journal of Glaucoma

Volumn 23, Issue 1, 2014, Pages

  Cucherat, Michel ^a   Stalmans, Ingeborg ^c   Rouland, Jean François ^b  

^a LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^b UNIV LILLE   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

intraocular pressure; latanoprost; meta analysis; open angle glaucoma

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; LATANOPROST; POLIDRONIUM CHLORIDE; T 2345; TRAVOPROST; UNCLASSIFIED DRUG;

ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; EMBASE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDLINE; META ANALYSIS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 84891838350     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3182a075e6     Document Type: Article

References (24)

1. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.
2. Vass C, Hirn C, Sycha T, et al. Medical Interventions for primary open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;CD003167.
3. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol. 2003;14:65-69.
4. Henry JC, Peace JH, Stewart JA, et al. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621.
5. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88: 329-336.
6. Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin Ophthalmol. 2011;5:623-631.
7. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196-200.
8. Denis PH, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23:601-608.
9. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs. A meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667-673.
10. Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjuntival hyperaemia with the use of latanoprost versus other prosta-glandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316-321.
11. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447-456.
12. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124.
13. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897-900.
14. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9: 1-134, iii-iv.
15. Caldwell DM, Gibb DM, Ades AE. Validity of indirect comparisons in meta-analysis. Lancet. 2007;369:270, Author reply 271.
16. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17. Haynes RB, McKibbon KA, Wilczynski NL, et al. Optimal search strategies for retrieving scientifically strong studies of treatment from MEDLINE: analytical survey. BMJ. 2005; 330:1179.
18. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
20. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691.
21. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003; 326:472.
22. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115:1320-1327.
23. Hollo G. The side effects of prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45-52.
24. Feldman FM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23-35.